Essex Bio-Tech Buys Back 23,000 Shares, Treasury Stock Rises to 2.07 Million

Bulletin Express09-15

Essex Bio-Technology Limited reported a further share repurchase conducted on 15 September 2026. The company acquired 23,000 ordinary shares on The Stock Exchange of Hong Kong at prices ranging from HKD 2.02 to HKD 2.045, representing a volume-weighted average cost of HKD 2.0352 per share. The transaction amounted to HKD 0.05 million in total consideration.

Following the buyback, Essex Bio-Tech’s outstanding share count (excluding treasury shares) decreased to 564.94 million, while the treasury-share balance increased to 2.07 million. The repurchased shares represent 0.0041 % of the company’s issued shares (excluding treasury shares) prior to the transaction. Total issued shares remain unchanged at 567.01 million as the repurchased shares are being held in treasury and have not been cancelled.

The purchase was made under the repurchase mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 56.70 million shares. Cumulative repurchases under this mandate now stand at 2.07 million shares, equivalent to 0.36 % of the issued share base at the mandate date. In accordance with Hong Kong listing rules, Essex Bio-Tech is restricted from issuing new shares or disposing of treasury shares until 15 October 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140061541?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140061541","market":"hk","top_or_hot":-1,"title":"Essex Bio-Tech Buys Back 23,000 Shares, Treasury Stock Rises to 2.07 Million","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited reported a further share repurchase conducted on 15 September 2026. The company acquired 23,000 ordinary shares on The Stock Exchange of Hong Kong at prices ranging from HKD 2.02 to HKD 2.045, representing a volume-weighted average cost of HKD 2.0352 per share. The transaction amounted to HKD 0.05 million in total consideration.</p>\n<p>Following the buyback, Essex Bio-Tech’s outstanding share count (excluding treasury shares) decreased to 564.94 million, while the treasury-share balance increased to 2.07 million. The repurchased shares represent 0.0041 % of the company’s issued shares (excluding treasury shares) prior to the transaction. Total issued shares remain unchanged at 567.01 million as the repurchased shares are being held in treasury and have not been cancelled.</p>\n<p>The purchase was made under the repurchase mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 56.70 million shares. Cumulative repurchases under this mandate now stand at 2.07 million shares, equivalent to 0.36 % of the issued share base at the mandate date. In accordance with Hong Kong listing rules, Essex Bio-Tech is restricted from issuing new shares or disposing of treasury shares until 15 October 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Tech Buys Back 23,000 Shares, Treasury Stock Rises to 2.07 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Tech Buys Back 23,000 Shares, Treasury Stock Rises to 2.07 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-15 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited reported a further share repurchase conducted on 15 September 2026. The company acquired 23,000 ordinary shares on The Stock Exchange of Hong Kong at prices ranging from HKD 2.02 to HKD 2.045, representing a volume-weighted average cost of HKD 2.0352 per share. The transaction amounted to HKD 0.05 million in total consideration.</p>\n<p>Following the buyback, Essex Bio-Tech’s outstanding share count (excluding treasury shares) decreased to 564.94 million, while the treasury-share balance increased to 2.07 million. The repurchased shares represent 0.0041 % of the company’s issued shares (excluding treasury shares) prior to the transaction. Total issued shares remain unchanged at 567.01 million as the repurchased shares are being held in treasury and have not been cancelled.</p>\n<p>The purchase was made under the repurchase mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 56.70 million shares. Cumulative repurchases under this mandate now stand at 2.07 million shares, equivalent to 0.36 % of the issued share base at the mandate date. In accordance with Hong Kong listing rules, Essex Bio-Tech is restricted from issuing new shares or disposing of treasury shares until 15 October 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1140061541","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140061541","pubTimestamp":1789461962,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited reported a further share repurchase conducted on 15 September 2026. The company acquired 23,000 ordinary shares on The Stock Exchange of Hong Kong at prices ranging from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"埃塞克斯生物技术公司回购 23,000 股股票，库存股增至 207 万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited reported a further share repurchase conducted on 15 September 2026. The company acquired 23,000 ordinary shares on The Stock Exchange of Hong Kong at prices ranging from HKD 2.02 to HKD 2.045, representing a volume-weighted average cost of HKD 2.0352 per share. The transaction amounted to HKD 0.05 million in total consideration.\nFollowing the buyback, Essex Bio-Tech’s outstanding share count (excluding treasury shares) decreased to 564.94 million, while the treasury-share balance increased to 2.07 million. The repurchased shares represent 0.0041 % of the company’s issued shares (excluding treasury shares) prior to the transaction. Total issued shares remain unchanged at 567.01 million as the repurchased shares are being held in treasury and have not been cancelled.\nThe purchase was made under the repurchase mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 56.70 million shares. Cumulative repurchases under this mandate now stand at 2.07 million shares, equivalent to 0.36 % of the issued share base at the mandate date. In accordance with Hong Kong listing rules, Essex Bio-Tech is restricted from issuing new shares or disposing of treasury shares until 15 October 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140061541","isCrawlerRequest":true}